Solid Biosciences (SLDB) Profit After Tax (2017 - 2026)

Solid Biosciences has reported Profit After Tax for 10 years, with the latest figure at -$56.7 million in Q1 2026.

• Quarterly Profit After Tax fell 44.44% year-over-year to -$56.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$191.8 million (down 37.3% YoY) and the FY2025 annual result came in at -$174.3 million, down 39.8% from the prior year.
• Profit After Tax fell to -$56.7 million in Q1 2026 per SLDB's latest filing, from -$49.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$15.2 million in Q4 2022 and troughed at -$56.7 million in Q1 2026.
• A 5-year average of -$31.6 million and a median of -$25.3 million in 2022 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 19.18% in 2024, down 109.47% in 2024.
• Over 5 years, Profit After Tax stood at -$15.2 million in 2022, then plunged by 34.22% to -$20.3 million in 2023, then tumbled by 109.47% to -$42.6 million in 2024, then decreased by 16.88% to -$49.8 million in 2025, then retreated by 13.96% to -$56.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$56.7 million, -$49.8 million, and -$45.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.